---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076837"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:32:14.180670+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%

## Summary
- YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.
- Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.
- Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.
- Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
- Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY.

## SEC filing metadata
- accession: 0001104659-25-076837
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/0001104659-25-076837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/tm2523183d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076837
- JSON: https://secwatch.observer/filing/0001104659-25-076837.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.